Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata

Detalhes bibliográficos
Autor(a) principal: Cordeiro, Elisângela Rosa
Data de Publicação: 2006
Tipo de documento: Tese
Idioma: por
Título da fonte: Repositório Institucional da UFU
Texto Completo: https://repositorio.ufu.br/handle/123456789/15690
Resumo: Prostate cancer (PCa) has become a serious problem of public health for men. It is the second most diagnosed cancer, and even with the improvement of the clinical, histopathology and chemical techniques of detection, there is still a high mortality rate in consequence of the delayed or inefficient diagnosis of the illness. Finding more specific markers to increase the possibilities of cure and detection of the illness has been the objective of numerous researches. Several components involved on the protein synthesis in eukaryotes have been related with the oncogenic transformation. The alteration on the mRNA levels of the elongation factor 1 (EF1A) expression has been related to different types of cancer. A mutated form of this gene, PTI-1, has been associated with prostate cancer. This gene has an exclusive region of homology to Mycoplasma hyopneumoniae, 5´UTR, and a region of fusion, which contains sequences of homology to the M. hyopneumoniae and to the EF1A. It was originally described in the cellular lineage LNCaP, and its expression has been detected in tumoral cells while corresponding normal cells were negative. Our goal was to analyze the behavior of the expression of those two genes in samples of blood and of patients with PCa, benign prostatic hiperplasia (BPH) and in blood of young healthy men (control). We observed that the expression of EF1A in blood as in tissue was higher in patients of the PCa group. The groups had been subdivided in expression intervals 0.5, 0.5 1.0, 1.0 1.5 and >1.5 for better characterization. The relative levels of expression of the EF1A in tissue were estatistically correlated with the TNM staging, and presented a risk 4.6 times higher of PCa occurrence. In the BPH group, 90% of the patients presented lower mRNA expression levels. In the peripheral blood, we have observed for the interval lower than 0.5 that the probability of being PCa is 3 times higher than in the 1.5 interval, with a risk 10.56 times higher. The 5 UTR and the fusion regions, although observed in high rates in the PCa group, it has also been observed in BPH and the control groups. Its presence associated with EF1A expression level leads us to hipothetize that this gene modulates the EF1A expression in initial and final periods of the illness, determining an increase of the EF1A levels in order to guarantee the cellular proliferation and advance of the tumor confined to the organ; when the passage to metastasis phase occurs, PTI-1 seems to exert a control on the levels of EF1A as to reduce them, thus preventing the cells in the circulation come to suffer apoptosis.
id UFU_1bb2656c8e34ddc8871268f95374804b
oai_identifier_str oai:repositorio.ufu.br:123456789/15690
network_acronym_str UFU
network_name_str Repositório Institucional da UFU
repository_id_str
spelling Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstataGenes EF1A e PTI-1Expressão gênicaRT_PCRCâncer de próstataPróstata - CâncerProstate cancerExpression geneEF1A and PTI-1 genesCNPQ::CIENCIAS BIOLOGICAS::GENETICAProstate cancer (PCa) has become a serious problem of public health for men. It is the second most diagnosed cancer, and even with the improvement of the clinical, histopathology and chemical techniques of detection, there is still a high mortality rate in consequence of the delayed or inefficient diagnosis of the illness. Finding more specific markers to increase the possibilities of cure and detection of the illness has been the objective of numerous researches. Several components involved on the protein synthesis in eukaryotes have been related with the oncogenic transformation. The alteration on the mRNA levels of the elongation factor 1 (EF1A) expression has been related to different types of cancer. A mutated form of this gene, PTI-1, has been associated with prostate cancer. This gene has an exclusive region of homology to Mycoplasma hyopneumoniae, 5´UTR, and a region of fusion, which contains sequences of homology to the M. hyopneumoniae and to the EF1A. It was originally described in the cellular lineage LNCaP, and its expression has been detected in tumoral cells while corresponding normal cells were negative. Our goal was to analyze the behavior of the expression of those two genes in samples of blood and of patients with PCa, benign prostatic hiperplasia (BPH) and in blood of young healthy men (control). We observed that the expression of EF1A in blood as in tissue was higher in patients of the PCa group. The groups had been subdivided in expression intervals 0.5, 0.5 1.0, 1.0 1.5 and >1.5 for better characterization. The relative levels of expression of the EF1A in tissue were estatistically correlated with the TNM staging, and presented a risk 4.6 times higher of PCa occurrence. In the BPH group, 90% of the patients presented lower mRNA expression levels. In the peripheral blood, we have observed for the interval lower than 0.5 that the probability of being PCa is 3 times higher than in the 1.5 interval, with a risk 10.56 times higher. The 5 UTR and the fusion regions, although observed in high rates in the PCa group, it has also been observed in BPH and the control groups. Its presence associated with EF1A expression level leads us to hipothetize that this gene modulates the EF1A expression in initial and final periods of the illness, determining an increase of the EF1A levels in order to guarantee the cellular proliferation and advance of the tumor confined to the organ; when the passage to metastasis phase occurs, PTI-1 seems to exert a control on the levels of EF1A as to reduce them, thus preventing the cells in the circulation come to suffer apoptosis.Doutor em Genética e BioquímicaA descoberta de marcadores moleculares que possam melhorar o diagnóstico clínico e as perspectivas de cura não só do câncer de próstata como de várias outras doenças tem se tornado o objetivo central da biologia molecular. Nosso trabalho teve por objetivo rever o papel do gene EF1A e do seu homólogo PTI-1 no câncer de próstata. Para tal, foram analisadas amostras de sangue periférico e tecido de peça cirúrgica provenientes de pacientes diagnosticados com hiperplasia prostática benigna (HPB) e câncer de próstata (CaP) e amostras de sangue de um grupo de homens jovens, considerados controle negativo (CN). Observamos que o gene EF1A tem níveis relativos de expressão maiores no grupo de pacientes do grupo Cap do que nos grupos de HPB e CN. Em sangue periférico, níveis relativos de expressão do EF1A maiores do 1,5, conferem uma razão de chances 10,56 vezes maior de o indivíduo apresentar CaP em relação aos com menores níveis de expressão. No tecido essa chance é de 4,6 vezes para níveis de expressão com média entre 1 e 1,5. A presença do transcrito do gene PTI-1, região 5 UTR, faz com que os indivíduos tenham uma chance 1,94 vezes maior de desenvolver CaP. A associação do biomarcador DD3 ao gene PTI-1 faz com que a chance de desenvolver CaP seja de 3,14 vezes maior quando esses dois genes são detectados simultaneamente. Embora tenhamos que melhorar a eficiência dos testes com os genes EF1A e PTI-1 para a aplicação clínica, possivelmente eles terão uma contribuição significativa, associados a outros biomarcadores, como por exemplo, o DD3, para o diagnóstico do CaP.Universidade Federal de UberlândiaBRPrograma de Pós-graduação em Genética e BioquímicaCiências BiológicasUFUGoulart Filho, Luiz Ricardohttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4781012P8Gimba, Etel Rodrigues Pereirahttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4727071A9Madurro, Ana Graci Britohttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4709037T3Bonetti, Ana Mariahttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4783660P9Freitas, Danielo Garcia dehttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4706492J6Cordeiro, Elisângela Rosa2016-06-22T18:43:19Z2008-10-072016-06-22T18:43:19Z2006-08-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisapplication/pdfapplication/pdfCORDEIRO, Elisângela Rosa. Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata. 2006. 102 f. Tese (Doutorado em Ciências Biológicas) - Universidade Federal de Uberlândia, Uberlândia, 2006.https://repositorio.ufu.br/handle/123456789/15690porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFUinstname:Universidade Federal de Uberlândia (UFU)instacron:UFU2016-06-23T07:13:54Zoai:repositorio.ufu.br:123456789/15690Repositório InstitucionalONGhttp://repositorio.ufu.br/oai/requestdiinf@dirbi.ufu.bropendoar:2016-06-23T07:13:54Repositório Institucional da UFU - Universidade Federal de Uberlândia (UFU)false
dc.title.none.fl_str_mv Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
title Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
spellingShingle Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
Cordeiro, Elisângela Rosa
Genes EF1A e PTI-1
Expressão gênica
RT_PCR
Câncer de próstata
Próstata - Câncer
Prostate cancer
Expression gene
EF1A and PTI-1 genes
CNPQ::CIENCIAS BIOLOGICAS::GENETICA
title_short Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
title_full Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
title_fullStr Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
title_full_unstemmed Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
title_sort Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata
author Cordeiro, Elisângela Rosa
author_facet Cordeiro, Elisângela Rosa
author_role author
dc.contributor.none.fl_str_mv Goulart Filho, Luiz Ricardo
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4781012P8
Gimba, Etel Rodrigues Pereira
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4727071A9
Madurro, Ana Graci Brito
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4709037T3
Bonetti, Ana Maria
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4783660P9
Freitas, Danielo Garcia de
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4706492J6
dc.contributor.author.fl_str_mv Cordeiro, Elisângela Rosa
dc.subject.por.fl_str_mv Genes EF1A e PTI-1
Expressão gênica
RT_PCR
Câncer de próstata
Próstata - Câncer
Prostate cancer
Expression gene
EF1A and PTI-1 genes
CNPQ::CIENCIAS BIOLOGICAS::GENETICA
topic Genes EF1A e PTI-1
Expressão gênica
RT_PCR
Câncer de próstata
Próstata - Câncer
Prostate cancer
Expression gene
EF1A and PTI-1 genes
CNPQ::CIENCIAS BIOLOGICAS::GENETICA
description Prostate cancer (PCa) has become a serious problem of public health for men. It is the second most diagnosed cancer, and even with the improvement of the clinical, histopathology and chemical techniques of detection, there is still a high mortality rate in consequence of the delayed or inefficient diagnosis of the illness. Finding more specific markers to increase the possibilities of cure and detection of the illness has been the objective of numerous researches. Several components involved on the protein synthesis in eukaryotes have been related with the oncogenic transformation. The alteration on the mRNA levels of the elongation factor 1 (EF1A) expression has been related to different types of cancer. A mutated form of this gene, PTI-1, has been associated with prostate cancer. This gene has an exclusive region of homology to Mycoplasma hyopneumoniae, 5´UTR, and a region of fusion, which contains sequences of homology to the M. hyopneumoniae and to the EF1A. It was originally described in the cellular lineage LNCaP, and its expression has been detected in tumoral cells while corresponding normal cells were negative. Our goal was to analyze the behavior of the expression of those two genes in samples of blood and of patients with PCa, benign prostatic hiperplasia (BPH) and in blood of young healthy men (control). We observed that the expression of EF1A in blood as in tissue was higher in patients of the PCa group. The groups had been subdivided in expression intervals 0.5, 0.5 1.0, 1.0 1.5 and >1.5 for better characterization. The relative levels of expression of the EF1A in tissue were estatistically correlated with the TNM staging, and presented a risk 4.6 times higher of PCa occurrence. In the BPH group, 90% of the patients presented lower mRNA expression levels. In the peripheral blood, we have observed for the interval lower than 0.5 that the probability of being PCa is 3 times higher than in the 1.5 interval, with a risk 10.56 times higher. The 5 UTR and the fusion regions, although observed in high rates in the PCa group, it has also been observed in BPH and the control groups. Its presence associated with EF1A expression level leads us to hipothetize that this gene modulates the EF1A expression in initial and final periods of the illness, determining an increase of the EF1A levels in order to guarantee the cellular proliferation and advance of the tumor confined to the organ; when the passage to metastasis phase occurs, PTI-1 seems to exert a control on the levels of EF1A as to reduce them, thus preventing the cells in the circulation come to suffer apoptosis.
publishDate 2006
dc.date.none.fl_str_mv 2006-08-30
2008-10-07
2016-06-22T18:43:19Z
2016-06-22T18:43:19Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv CORDEIRO, Elisângela Rosa. Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata. 2006. 102 f. Tese (Doutorado em Ciências Biológicas) - Universidade Federal de Uberlândia, Uberlândia, 2006.
https://repositorio.ufu.br/handle/123456789/15690
identifier_str_mv CORDEIRO, Elisângela Rosa. Modulação da expressão dos genes EF1A e PTI-1 no câncer de próstata. 2006. 102 f. Tese (Doutorado em Ciências Biológicas) - Universidade Federal de Uberlândia, Uberlândia, 2006.
url https://repositorio.ufu.br/handle/123456789/15690
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Uberlândia
BR
Programa de Pós-graduação em Genética e Bioquímica
Ciências Biológicas
UFU
publisher.none.fl_str_mv Universidade Federal de Uberlândia
BR
Programa de Pós-graduação em Genética e Bioquímica
Ciências Biológicas
UFU
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFU
instname:Universidade Federal de Uberlândia (UFU)
instacron:UFU
instname_str Universidade Federal de Uberlândia (UFU)
instacron_str UFU
institution UFU
reponame_str Repositório Institucional da UFU
collection Repositório Institucional da UFU
repository.name.fl_str_mv Repositório Institucional da UFU - Universidade Federal de Uberlândia (UFU)
repository.mail.fl_str_mv diinf@dirbi.ufu.br
_version_ 1813711438591557632